EP4 Receptor Antagonists for Cartilage Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic methods for cartilage disease are only palliative and lack sufficient effectiveness in preventing or treating cartilage degeneration, with a need for novel agents that can effectively suppress cartilage destruction and promote cartilage regeneration.
Innovation Solution
Development of compounds with selective EP4 receptor antagonism, specifically formulated compounds of formula (I), (II), (III), (IV), or (Va), or their pharmaceutically acceptable salts, which are administered to treat cartilage diseases by inhibiting cartilage destruction and promoting calcification in cartilage explant models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic methods (analgesic antiinflammatory agents or hyaluronic acid formulations) are used to treat cartilage disease, then pain relief is provided, but the treatment is only palliative and does not sufficiently suppress cartilage destruction or promote regeneration
Solution Approach 1:
The patent employs parameter changes by modifying the biochemical environment through EP4 receptor antagonism. The compound changes the signaling parameters of prostaglandin E2 pathways in cartilage cells, shifting the balance from destruction to regeneration. This is achieved by selectively blocking EP4 receptors, which alters cellular responses to PGE2 and promotes anabolic processes while inhibiting catabolic activities.
Solution Approach 2:
The EP4 receptor antagonist acts as an intermediary substance that mediates the interaction between prostaglandin E2 and cartilage cells. By introducing this intermediary compound, the patent modifies the natural signaling pathway to achieve therapeutic effects. The antagonist serves as a bridge that converts the harmful PGE2-EP4 interaction into a beneficial therapeutic mechanism that suppresses destruction and promotes regeneration.
2Reliability
If EP4 receptor antagonists are used to suppress cartilage destruction and promote regeneration, then therapeutic effectiveness is improved, but the complexity of the treatment mechanism increases compared to conventional palliative therapies
Solution Approach 1:
The patent extracts and isolates the specific EP4 receptor pathway from the complex web of prostaglandin signaling. By focusing selectively on EP4 antagonism rather than broad anti-inflammatory mechanisms, the treatment simplifies the approach while maintaining high effectiveness. This extraction of the specific therapeutic target from the broader inflammatory pathway allows for precise intervention with a single mechanism of action.
Data Source
AI summary
The invention is a method of treating osteoarthritis or normalizing a condition of osteoarthritis comprising administering to an animal or a human in need thereof a therapeutically effective amount of 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea or a pharmaceutically acceptable salt thereof.